Dr. Amescua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s allogeneic adult stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.
(PRWEB) June 24, 2010 -- Stemedica Cell Technologies, Inc., a leader in allogeneic adult stem cell manufacturing, research and development announced today the appointment of César Amescua, MD as Medical and Regulatory Affairs Director for Latin America. Dr. Amescua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.
Dr. Amescua is a member of the senior medical leadership at Groupo Angeles, one of the largest health care providers in all of Latin America. He is also President of the Mexican Association for the Study and Treatment of Pain. "I am excited and proud to be working with Stemedica. The company is a leader in the stem cell manufacturing field, and is bringing innovative technology to countries around the world. Latin America holds great promise for Stemedica’s products and services as Latin America seeks to address the epidemic of degenerative diseases and conditions that are bankrupting health care systems around the world."
Dr. Lev Verkh, Stemedica’s Chief Regulatory and Clinical Development Officer, commented, "We’re pleased and delighted to have Dr. Amescua joining our team at Stemedica. His medical leadership and his regulatory expertise will be critical in establishing clinical trials throughout Latin America using Stemedica stem
Copyright©2010 Vocus, Inc.
All rights reserved